Go online to PeerView.com/GUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent symposium held during the 2023 ASCO Annual Meeting, leading experts guide you through the winning era of immunotherapy in melanoma. Through a series of linked lectures and debates, the panel discusses the integration of modern immunotherapy combination and sequential options in advanced disease and considers options for patients progressing on prior immunotherapy. They also examine new developments with immunotherapy in the adjuvant and neoadjuvant settings. Upon completion of this activity, participants should be better able to: Discuss current guidelines, efficacy, and safety data surrounding the use of immunotherapy in melanoma as neoadjuvant or adjuvant therapy in resectable disease or as part of novel combinatorial or sequential approaches for unresectable disease; Craft team-based treatment plans that include immunotherapy for resectable and unresectable melanoma, including BRAF-mutant or BRAF wild-type disease, based on updated evidence and guideline recommendations; and Develop management strategies for the unique adverse events associated with immunotherapy for patients with melanoma across the spectrum of disease.

0 Comments Sort By